Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
Holding LEGN?
Track your performance easily

Legend Biotech (LEGN) Stock Forecast & Price Target

311 Followers
See the Price Targets and Ratings of:

LEGN Analyst Ratings

Strong Buy
13Ratings
12 Buy
1 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Legend
Biotech
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

LEGN Stock 12 Month Forecast

Average Price Target

$84.27
▲(75.34% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Legend Biotech in the last 3 months. The average price target is $84.27 with a high forecast of $94.00 and a low forecast of $67.00. The average price target represents a 75.34% change from the last price of $48.06.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"44":"$44","95":"$95","56.75":"$56.8","69.5":"$69.5","82.25":"$82.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$94.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":84.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$84.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$67.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[44,56.75,69.5,82.25,95],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2024","6":"Apr<br/>2024","9":"Jul<br/>2024","12":"Oct<br/>2024","25":"Oct<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.07,52.526153846153846,55.98230769230769,59.43846153846154,62.894615384615385,66.35076923076923,69.80692307692308,73.26307692307692,76.71923076923076,80.17538461538462,83.63153846153847,87.08769230769231,90.54384615384615,{"y":94,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.07,51.777692307692305,54.48538461538462,57.19307692307692,59.90076923076923,62.60846153846154,65.31615384615384,68.02384615384615,70.73153846153846,73.43923076923076,76.14692307692307,78.85461538461539,81.56230769230768,{"y":84.27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,49.07,50.449230769230766,51.82846153846154,53.207692307692305,54.58692307692308,55.966153846153844,57.34538461538462,58.72461538461538,60.103846153846156,61.48307692307692,62.862307692307695,64.24153846153847,65.62076923076923,{"y":67,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":67.27,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.97,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.99,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.44,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.76,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.53,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.93,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.41,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.57,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.3,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.68,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.29,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.07,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$94.00Average Price Target$84.27Lowest Price Target$67.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG
$91
Buy
89.35%
Upside
Reiterated
07/17/24
BTIG reiterates Buy Rating on Legend Biotech Corp. (LEGN)BTIG analyst Justin Zelin reiterated a Buy rating and $91.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).
TD Cowen
$71$67
Buy
39.41%
Upside
Reiterated
07/15/24
Legend Biotech price target lowered to $67 from $71 at TD CowenLegend Biotech price target lowered to $67 from $71 at TD Cowen
Deutsche Bank
$60
Buy
24.84%
Upside
Reiterated
07/02/24
Buy Rating Affirmed for Legend Biotech Amid Promising Carvykti Trial Results and Expert Endorsements
Morgan Stanley
$85$82
Buy
70.62%
Upside
Reiterated
05/17/24
Legend Biotech Corp. (LEGN) PT Lowered to $82 at Morgan StanleyMorgan Stanley analyst Matthew Harrison lowered the price target on Legend Biotech Corp. (NASDAQ: LEGN) to $82.00 (from $85.00) while maintaining a Overweight rating.
Cantor Fitzgerald
$82
Buy
70.62%
Upside
Initiated
04/03/24
Legend Biotech initiated with an Overweight at Cantor FitzgeraldLegend Biotech initiated with an Overweight at Cantor Fitzgerald

Best Analysts Covering Legend Biotech

Which Analyst Should I Follow If I Want to Buy LEGN and Sell After:
1 Month
xxx
Success Rate
8/12 ratings generated profit
67%
Average Return
+2.38%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +2.38% per trade.
3 Months
xxx
Success Rate
6/10 ratings generated profit
60%
Average Return
+14.04%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +14.04% per trade.
1 Year
Matthew HarrisonMorgan Stanley
Success Rate
8/10 ratings generated profit
80%
Average Return
+26.70%
reiterated a buy rating 5 months ago
Copying Matthew Harrison's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +26.70% per trade.
2 Years
xxx
Success Rate
7/10 ratings generated profit
70%
Average Return
+19.27%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 70.00% of your transactions generating a profit, with an average return of +19.27% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LEGN Analyst Recommendation Trends

Rating
Jun 24
Jul 24
Aug 24
Sep 24
Oct 24
Strong Buy
36
25
15
15
10
Buy
7
7
9
10
5
Hold
4
1
1
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
47
33
25
27
17
In the current month, LEGN has received 15 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. LEGN average Analyst price target in the past 3 months is $84.27.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

LEGN Financial Forecast

LEGN Earnings Forecast

Next quarter’s earnings estimate for LEGN is -$0.34 with a range of -$0.70 to -$0.19. The previous quarter’s EPS was -$0.05. LEGN beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.68% of the time in the same period. In the last calendar year LEGN has Outperformed its overall industry.
Next quarter’s earnings estimate for LEGN is -$0.34 with a range of -$0.70 to -$0.19. The previous quarter’s EPS was -$0.05. LEGN beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.68% of the time in the same period. In the last calendar year LEGN has Outperformed its overall industry.

LEGN Sales Forecast

Next quarter’s sales forecast for LEGN is $136.11M with a range of $113.30M to $148.53M. The previous quarter’s sales results were $186.52M. LEGN beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 46.60% of the time in the same period. In the last calendar year LEGN has Underperformed its overall industry.
Next quarter’s sales forecast for LEGN is $136.11M with a range of $113.30M to $148.53M. The previous quarter’s sales results were $186.52M. LEGN beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 46.60% of the time in the same period. In the last calendar year LEGN has Underperformed its overall industry.

LEGN Stock Forecast FAQ

What is LEGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Legend Biotech Corporation’s 12-month average price target is $84.27.
    What is LEGN’s upside potential, based on the analysts’ average price target?
    Legend Biotech Corporation has 75.34% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is LEGN a Buy, Sell or Hold?
          Legend Biotech Corporation has a consensus rating of Strong Buy which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Legend Biotech Corporation’s price target?
            The average price target for Legend Biotech Corporation is $84.27. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $94.00 ,the lowest forecast is $67.00. The average price target represents 75.34% Increase from the current price of $48.06.
              What do analysts say about Legend Biotech Corporation?
              Legend Biotech Corporation’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of LEGN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis